Bevacizumab: A compassionate way of doing business? [38]

Eye

Volumn 21, Issue 6, 2007, Pages 890-891

  Spratt, A ^a   Ogunbowale, L ^a   Franks, W ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

BLINDNESS; CLINICAL EFFECTIVENESS; DRUG INDICATION; DRUG SAFETY; ENUCLEATION; EYE PAIN; HUMAN; INTRAOCULAR HEMORRHAGE; LASER COAGULATION; LETTER; NEOVASCULAR GLAUCOMA; PATIENT ATTITUDE; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; RISK REDUCTION; SURGICAL DRAINAGE;

EID: 34250316193     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702776     Document Type: Letter

References (3)

1. Canning C, Lotery A. Bevacizumab: A new way of doing business? Eye 2006; 20: 985-987.
2. The Central Vein Occlusion Study. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
3. Grisanti S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt K. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-159.